Cite
HARVARD Citation
Oaknin, A. et al. (n.d.). 2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine. International journal of gynecological cancer. pp. A251-A252. [Online].